Myo-Inositol
Myo-Inositol
A B-vitamin-like compound that supports insulin sensitivity, fertility, mood, and is particularly beneficial for PCOS and anxiety.
Myo-Inositol is the most abundant form of inositol in the body, playing crucial roles in insulin signaling, cell membrane formation, and neurotransmitter function. It has become a first-line natural treatment for PCOS (polycystic ovary syndrome), improving insulin sensitivity, ovulation, and hormone balance. Beyond reproductive health, inositol shows significant benefits for anxiety, panic disorder, and OCD through its effects on serotonin signaling.
Mechanisms of Action
Insulin Signaling
Acts as a second messenger in insulin pathways
Serotonin Modulation
Enhances serotonin receptor sensitivity
Ovarian Function
Supports healthy egg development and ovulation
Recommended Dose
2-4g daily for PCOS; up to 12-18g for anxiety
Loading: Start with 2g and increase gradually. PCOS typically uses 2-4g; anxiety disorders may use 12-18g.
Optimal Timing
- Divided doses with meals
- Morning and evening
Take with food
Best Form
Myo-inositol powder
Alternatives: Capsules, Myo-inositol + D-chiro-inositol combinations
Powder is most cost-effective for higher doses. 40:1 ratio of myo to D-chiro-inositol mimics natural physiological ratio and is often used for PCOS.
Duration
Minimum: 8 weeks
Optimal: 24 weeks
Cycling: Not required
Note: Often combined with D-chiro-inositol in 40:1 ratio for PCOS. For anxiety, higher doses divided throughout the day.
Personalized Dosage Calculator
Get a dosage recommendation tailored to your body weight, age, goals, and health profile.
Set up your health profile for personalized recommendations
Improved Ovulation
More regular menstrual cycles and ovulation
Reduced Anxiety
Decreased anxiety and panic symptoms
Better Insulin Sensitivity
Improved blood sugar regulation
GI Effects
May cause nausea or diarrhea at high doses
Often used for gestational diabetes prevention; consult healthcare provider
First-line natural treatment; well-studied
Who Should NOT Take This
- Bipolar disorder (may trigger mania at high doses)
Drug Interactions
Lithium depletes inositol; supplementation may help but consult psychiatrist
May enhance blood sugar lowering; monitor glucose
Possible Side Effects
Tip: Take with food; start with lower dose
Tip: Reduce dose; divide doses throughout day
Warnings
- High doses (12g+) needed for anxiety effects
- Use caution in bipolar disorder
Top studies from 40+ peer-reviewed papers
Motuhifonua SK et al. • The Cochrane database of systematic reviews (2023)
“Evidence from seven studies shows that antenatal dietary supplementation with myo-inositol during pregnancy may reduce the incidence of gestational diabetes, hypertensive disorders of pregnancy and preterm birth.”
Key Findings:
- For the primary neonatal outcomes, only one study measured the risk of a large-for-gestational-age infant and found myo-inositol was associated with both appreciable benefit and harm (RR 1.40, 95% CI 0.65 to 3.02; 1 study, 234 infants; low-certainty evidence).
- Further, myo-inositol may result in little to no difference in caesarean section (RR 0.91, 95% CI 0.77 to 1.07; 4 studies, 829 women; low-certainty evidence).
- For the secondary neonatal outcomes, meta-analysis showed no neonatal hypoglycaemia (RR 3.07, 95% CI 0.90 to 10.52; 4 studies; 671 infants; very low-certainty evidence).
- However, myo-inositol may be associated with a reduction in the incidence of preterm birth (RR 0.35, 95% CI 0.17 to 0.70; 4 studies; 829 infants).
Wei J et al. • Nutrients (2022)
“In conclusion, 4 g MI nutritional supplementation per day during early pregnancy may reduce GDM incidence and severity, therefore may be a practical and safe approach for the prevention of GDM.”
Key Findings:
- Pooled results were expressed as relative risk (RR) or mean difference (MD) with a 95% confidence interval (95% CI).
- Compared with the control group, 4 g myo-inositol (MI) supplementation per day significantly decreased the incidence of GDM (RR = 0.30, 95% CI (0.18, 0.49), p < 0.00001).
- It also decreased the need of insulin treatment, and reduced the incidence of preterm delivery and neonatal hypoglycemia.
- However, no difference was observed between 1.1 g MI per day plus 27.6 mg D-chiro-inositol (DCI) per day and the control group regarding all evaluated results.
Zhang JQ et al. • European review for medical and pharmacological sciences (2022)
“Compared with metformin, the suitable supplemental dosage of myo-ins may be helpful in lowering levels of TG and avoiding adverse events (AEs).”
Key Findings:
- Compared with metformin, the suitable supplemental dosage of myo-ins may be helpful in lowering levels of TG and avoiding adverse events (AEs).
- Published in European review for medical and pharmacological sciences (2022)
- Further research warranted to confirm findings
Showell MG et al. • The Cochrane database of systematic reviews (2020)
“In this review, there was low- to very low-quality evidence to show that taking an antioxidant may benefit subfertile women.”
Key Findings:
- Due to the very low-quality of the evidence we are uncertain whether antioxidants improve live birth rate compared with placebo or no treatment/standard treatment (odds ratio (OR) 1.81, 95% confidence interval (CI) 1.36 to 2.43; P < 0.001, I2 = 29%; 13 RCTs, 1227 women).
- This suggests that among subfertile women with an expected live birth rate of 19%, the rate among women using antioxidants would be between 24% and 36%.
- Low-quality evidence suggests that antioxidants may improve clinical pregnancy rate compared with placebo or no treatment/standard treatment (OR 1.65, 95% CI 1.43 to 1.89; P < 0.001, I2 = 63%; 35 RCTs, 5165 women).
- This suggests that among subfertile women with an expected clinical pregnancy rate of 19%, the rate among women using antioxidants would be between 25% and 30%.
Morley LC et al. • The Cochrane database of systematic reviews (2017)
“Our updated review suggests that metformin alone may be beneficial over placebo for live birth, although the evidence quality was low.”
Key Findings:
- Metformin versus placebo or no treatmentThe evidence suggests that metformin may improve live birth rates compared with placebo (OR 1.59, 95% CI 1.00 to 2.51, 4 studies, 435 women, I2 = 0%, low-quality evidence).
- There was no clear evidence of a difference in miscarriage rates (OR 1.08, 95% CI 0.50 to 2.35, 4 studies, 748 women, I2 = 0%, low-quality evidence).
- However, the combined therapy group had higher rates of clinical pregnancy (OR 1.59, 95% CI 1.27 to 1.99, 16 studies, 1529 women, I2 = 33%, moderate-quality evidence) and ovulation (OR 1.57, 95% CI 1.28 to 1.92, 21 studies, 1624 women, I2 = 64%, moderate-quality evidence).
- Metformin versus clomiphene citrateWhen all studies were combined, findings for live birth were inconclusive and inconsistent (OR 0.71, 95% CI 0.49 to 1.01, 5 studies, 741 women, I2 = 86%, very low-quality evidence).
Study Type Distribution
Goals This Supplement Supports
Related Goals
This information is for educational purposes only and is not intended as medical advice. Always consult a qualified healthcare provider before starting any supplement.